Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.9250
-0.0750 (-7.50%)
Jun 27, 2025, 12:36 PM - Market open
Company Description
Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China.
The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy.
It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia.
The company was incorporated in 2010 and is headquartered in Houston, Texas.
Nexalin Technology, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Sep 16, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark White |
Contact Details
Address: 1776 Yorktown, Suite 550 Houston, Texas 77056 United States | |
| Phone | 832-260-0222 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B201 |
| ISIN Number | US65345B2016 |
| Employer ID | 27-5566468 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Mark White | President, Chief Executive Officer, Chief Financial Officer and Director |
| Carolyn Shelton | Executive Vice President of Clinical, Quality and Regulatory Affairs and Chief Operating Officer |
| Dr. David Owens M.D. | Chief Medical Officer, Member of Scientific Advisory Board and Director |
| Marilyn Elson | Controller |
| John Patrick Claude | Co-Founder and Director of Engineering and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 9, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| May 6, 2025 | 424B4 | Prospectus |
| May 5, 2025 | 424B5 | Filing |
| May 5, 2025 | 8-K | Current Report |
| May 2, 2025 | 424B4 | Prospectus |
| Apr 29, 2025 | EFFECT | Notice of Effectiveness |
| Apr 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |